Capital Increase / Dilution2026-05-27

Paid-in Capital Increase Decision Amendment

ADB

애드바이오텍

179530

-0.60

Signal Score

54CNeutral
Score54 / 100

Historical Avg Return (5d)

+0.72%

Data Coverage

100%n=2249

Risk-adjusted indicator based on 2249 historical DART filings. For informational purposes only — not investment advice.

Financial Impact

NEGATIVE

Key Numbers

  • • Event Type: Paid-in Capital Increase

AI Analysis Summary

ADBIOTECH Co.,Ltd. has announced an amendment to its decision regarding a paid-in capital increase. While specific figures are not available, a capital increase typically leads to share dilution, potentially negatively impacting existing shareholder value. The purpose of the funds and the issuance price would be critical for a more detailed assessment.

Risk Factors

Pro plan

Access Full Korean Market Signal Analytics

✔ AI-parsed DART filing classification & scoring

✔ Real-time event impact indicators

✔ Price reaction & historical pattern data

This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.

AI-processed analysis. Based on: [기재정정]주요사항보고서(유상증자결정). Source: Financial Supervisory Service (금융감독원 전자공시시스템). Raw government data is not redistributed. Not investment advice.